Page 2 - Polypid Ltd News Today

PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript February 14, 2024 PolyPid Ltd. misses on earnings expectations. Reported EPS is $-3.97 EPS, expectations were $-2.17. PolyPid Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greeting morning and welcome to […]

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash ...

PolyPid (NASDAQ:PYPD – Get Free Report) and Assure (NASDAQ:IONM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Risk and Volatility PolyPid has a beta of 1.45, […]

Shares of Applied Therapeutics, Inc.

Former Biogen CEO Michel Vounatsos Joins Quris-AI Board; Yossi Ben Amram Appointed President as BioAI Innovator Continues to Expand...

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 1,000 shares, a decline of 68.8% from the October 31st total of 3,200 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average […]

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Preventio...

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...

Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of...

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 1,500 shares, a drop of 88.7% from the August 31st total of 13,300 shares. Based on an average trading volume of 5,500 shares, the short-interest ratio is […]